Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 113Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 52Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 26Breast Neoplasms 25Lung Neoplasms 24Neoplasms 23Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Recurrence 17Non-Muscle Invasive Bladder Neoplasms 16Gallbladder Neoplasms 15Fallopian Tube Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Uterine Cervical Neoplasms 8Adenocarcinoma 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

Carboplatin 6pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2130-nm albumin-bound paclitaxel 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Gemcitabine × 1 year × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡